Navigation Links
TWi Pharmaceuticals Announces Tentative ANDA Approval for Guanfacine Hydrochloride Extended-Release Tablets
Date:5/14/2013

TAIPEI, Taiwan, May 14, 2013 /PRNewswire/ -- TWi Pharmaceuticals, Inc. (Taiwan OTC: 4180) today announced that it has received tentative approval for its Abbreviated New Drug Application (ANDA) for Guanfacine Hydrochloride Extended Release Tablets 1mg, 2mg, 3mg and 4mg from the United States Food and Drug Administration (U.S. FDA). Guanfacine Hydrochloride Extended-Release Tablet is a central alpha2A-adrenergic receptor agonist indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications.

"We are pleased to receive the tentative approval from U.S. FDA for our Guanfacine Hydrochloride product," said Dr. Calvin C. Chen , President of TWi Pharmaceuticals. "TWi had already reached a settlement agreement with the branded product manufacturer and intends to begin shipping its Guanfacine Hydrochloride product upon receiving the final approval from U.S. FDA."

According to IMS Health, a market research firm, the total annual sales of the branded product, Intuniv®, marketed by Shire US Inc., in U.S. were approximately $448 million in 2012.

About TWi Pharmaceuticals, Inc.

TWi Pharmaceuticals, Inc. is a leading specialty pharmaceutical company based in Taipei, Taiwan, focusing on the development of high barrier generic prescription products ranging from oral controlled release dosage form to novel drug delivery systems including the utilization of nanoparticles, transdermal, and polymeric oral delivery systems. Leveraging its internal research and development capabilities, together with operational flexibility, process development, manufacturing and regulatory expertise, TWi Pharmaceuticals concentrates on products and technologies that present significant barriers to entry or offer Paragraph IV first-to-file or first-to-market opportunities in the United States. For more information of TWi Pharmaceuticals, please visit www.twipharma.com.

Contact:

Michael L. Huang
Head of Investor Relations
Tel: +886-2-2657-3350
Email: michael.huang@twipharma.com


'/>"/>
SOURCE TWi Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. GW Pharmaceuticals to Report Interim 2013 Results and Host Conference Call on 3 June, 2013
2. Jazz Pharmaceuticals Announces Participation In Upcoming Investor Events
3. Anthera Pharmaceuticals Reports 2013 First Quarter Financial Results
4. Arbor Pharmaceuticals Announces FDA Approval of First NDA
5. Optimer Pharmaceuticals Appoints Eric Sirota as Chief Operating Officer
6. Valeant Pharmaceuticals To Webcast 2013 Annual Meeting Of Shareholders
7. Isis Pharmaceuticals to Present at the 2013 UBS Global Healthcare Conference
8. Actinium Pharmaceuticals, Inc. Receives Notice of Patent Allowance for a Key Application
9. Valeant Pharmaceuticals International, Inc. Announces Additional Information Regarding Continuance Proposal
10. Auxilium Pharmaceuticals, Inc. To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference
11. The Zacks Analyst Blog Highlights: Exxon Mobil, Statoil, Chevron, Braskem and Cubist Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... -- Research and Markets has announced the addition of the ... 2025" report to their offering. ... The Global Empty Capsules Market is poised to grow at ... $2.9 billion by 2025. This industry report analyzes the ... well as regional levels presented in the research scope. The study provides ...
(Date:2/24/2017)... , Feb. 24, 2017  In conjunction with DURECT ... financial results press release, you are invited to listen ... over the internet on Tuesday, March 14, 2017 at ... A live audio webcast of the presentation will ... and clicking "Investor Relations."  If you are unable ...
(Date:2/24/2017)... Feb. 23, 2017 Report analyzes the worldwide markets ... comprehensive analytics for the US, Canada , ... Asia-Pacific , Latin America ... provided for the period 2015 through 2022. Also, a six-year ... analytics are derived from primary and secondary research. Company profiles ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... The California State University Institute for Palliative ... in or interested in palliative care education and research. The Symposium, “Innovate. Investigate. ... County San Diego on Sept. 28 and 29, 2017, on the campus of California ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... which specializes in thought leadership , media relations, social media, content marketing ... that will be powered through Act-On, an intuitive marketing automation platform. , Rosica ...
(Date:2/23/2017)... ... February 23, 2017 , ... The 89th Academy Awards will ... the 2016 National Education Policy Center Bunkum Award. We invite you to enjoy our ... This year’s Bunkum winner is the Center for American Progress (CAP), for its report, ...
(Date:2/23/2017)... ... , ... Hamlin Dental Group and Dr. Hamid Reza, dentist in North ... month of February, patients who visit Hamlin Dental Group will receive a ticket for ... at the Cheesecake Factory. , Tickets are available for routine dental visits and ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... new, interactive publication where generations converge and explore the world from different perspectives. ... Dialog Magazine enables readers to gain understanding, increase empathy, and find greater happiness. ...
Breaking Medicine News(10 mins):